Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Andreas Möller's Biography



Andreas Möller, Associate Professor, QIMR Berghofer Medical Research Institute

Dr. Andreas Möller is Group Leader of the Tumour Microenvironment Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. He is also Adjunct Associate Professor with the Faculty of Medicine at the University of Queensland, and the School of Biomedical Science at the Queensland University of Technology. He joined the QIMR Berghofer in November 2012 after being Peter Mac Research Fellow at the Peter MacCallum Cancer Centre, Melbourne. He conducted his doctoral work at the German Cancer Research Centre (DKFZ) in Heidelberg and an initial postdoc at the University of Berne, Switzerland. His research theme involves the fields of cancer immunology, cancer biology, nanotechnology and metastasis. Dr. Möller is heading a research team consisting of 2 Postdocs, 3 PhD students and one Honours student.

Andreas Möller Image

Protein Content of Extracellular Vesicles as Biomarker in Cancer

Monday, 9 September 2019 at 17:00

Add to Calendar ▼2019-09-09 17:00:002019-09-09 18:00:00Europe/LondonProtein Content of Extracellular Vesicles as Biomarker in CancerCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com

Despite significant therapeutic advances, cancer remains a leading cause of death worldwide. A significant clinical problem is the generally late discovery of a cancer and the uncertainty of choosing the most effective therapy for the individual patient. Several novel biomarkers are proposed, ranging from genetic and genomic evaluations of the cancer or the cancer material in circulation to assessing nucleic acids, proteins or lipids. Accurate cancer biomarkers, in particular non-invasive liquid biomarkers based on blood samples or other body fluids, will allow clinicians to identify cancer patients early, triage them to the most appropriate intervention and follow the response of the cancer in real time over the course of the therapy.

In this presentation, I will share data on a novel biomarker for Non-Small-Cell Lung Cancer (NSCLC). We have developed a blood-based multi-protein signature capable of accurately prognosticating clinical outcome in NSCLC patient cohorts. This signature is contained in small circulating nano-vesicles termed exosomes. Overall, this work describes a novel prognostic biomarker signature to identify early stage NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalized adjuvant treatment decisions.


Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com